Skip to main content
Journal cover image

Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.

Publication ,  Journal Article
Zheng, T; Sheng, L; Wu, Y; Zhu, X; Yang, Y; Zhang, X; Bashir, MR; Ronot, M; Sun, H-C; Wang, Y; Song, B; Jiang, H
Published in: Eur J Radiol
March 2025

PURPOSE: To develop and validate an MRI-based model for predicting postoperative early (≤2 years) recurrence-free survival (RFS) in patients receiving upfront surgical resection (SR) for beyond Milan hepatocellular carcinoma (HCC) and to assess the model's performance in separate patients receiving neoadjuvant therapy for similar-stage tumors. METHOD: This single-center retrospective study included consecutive patients with resectable BCLC A/B beyond Milan HCC undergoing upfront SR or neoadjuvant therapy. All images were independently evaluated by three blinded radiologists. In patients receiving upfront SR, an MRI-based Early Recurrence Outside Milan (EROM) score was developed and validated for predicting early RFS via Cox regression analyses and compared with the BCLC staging system. In separate patients undergoing neoadjuvant therapy, interval tumor progression rate and postoperative early RFS were compared between EROM-predicted high- and low-risk groups. RESULTS: 279 patients (median, 56 years; 236 men) were included, 220 (78.9 %) undergoing upfront SR and 59 (21.1 %) received transarterial chemoembolization-based neoadjuvant therapy. Alpha-fetoprotein > 20 ng/mL (HR, 2.03; P = 0.007), size of the largest tumor (HR, 1.10; P = 0.016), infiltrative appearance (HR, 2.20; P = 0.032), and < 50 % arterial phase hyperenhancement (HR, 1.74; P = 0.023) formed the EROM score, with superior testing dataset C-index than the BCLC system (0.69 vs. 0.52, P < 0.001). The EROM-predicted high-risk (>15.3 points) patients had higher tumor progression (25.0 % vs. 0.0 %, P = 0.033) and lower postoperative 2-year RFS (16.0 % vs. 39.3 %, P = 0.025) rates after neoadjuvant therapy. CONCLUSIONS: In patients with resectable beyond Milan HCC, EROM allowed noninvasive prediction of postoperative early RFS and informed interval tumor progression risks after neoadjuvant therapy.

Duke Scholars

Published In

Eur J Radiol

DOI

EISSN

1872-7727

Publication Date

March 2025

Volume

184

Start / End Page

111945

Location

Ireland

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zheng, T., Sheng, L., Wu, Y., Zhu, X., Yang, Y., Zhang, X., … Jiang, H. (2025). Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC. Eur J Radiol, 184, 111945. https://doi.org/10.1016/j.ejrad.2025.111945
Zheng, Tianying, Liuji Sheng, Yuanan Wu, Xiaomei Zhu, Yang Yang, Xiaoyun Zhang, Mustafa R. Bashir, et al. “Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.Eur J Radiol 184 (March 2025): 111945. https://doi.org/10.1016/j.ejrad.2025.111945.
Zheng T, Sheng L, Wu Y, Zhu X, Yang Y, Zhang X, et al. Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC. Eur J Radiol. 2025 Mar;184:111945.
Zheng, Tianying, et al. “Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC.Eur J Radiol, vol. 184, Mar. 2025, p. 111945. Pubmed, doi:10.1016/j.ejrad.2025.111945.
Zheng T, Sheng L, Wu Y, Zhu X, Yang Y, Zhang X, Bashir MR, Ronot M, Sun H-C, Wang Y, Song B, Jiang H. Imaging-based prediction of early recurrence and neoadjuvant therapy outcomes for resectable beyond Milan HCC. Eur J Radiol. 2025 Mar;184:111945.
Journal cover image

Published In

Eur J Radiol

DOI

EISSN

1872-7727

Publication Date

March 2025

Volume

184

Start / End Page

111945

Location

Ireland

Related Subject Headings

  • Treatment Outcome
  • Retrospective Studies
  • Nuclear Medicine & Medical Imaging
  • Neoplasm Recurrence, Local
  • Neoadjuvant Therapy
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Liver Neoplasms
  • Humans